CHINA China Sinopharm's COVID-19 vaccine starts phase-3 clinical trials in Argentina

CHINA

China Sinopharm's COVID-19 vaccine starts phase-3 clinical trials in Argentina

CGTN

19:53, August 22, 2020

A Chinese inactivated COVID-19 vaccine has received approval for phase-3 clinical trials in Argentina on Friday, according to the vaccine developer China National Biotec Group (CNBG) affiliated to Sinopharm.

CNBG will work with Elea Phoenix Laboratory of Argentina in terms of the development and promotion of the vaccine, said the Chinese company in a statement on Friday. 

图3.png

A screenshot of a CNBG poster

This is another important step forward for China's international cooperation in developing a COVID-19 vaccine. The inactivated COVID-19 vaccine received approval for phase-3 clinical trials in the United Arab Emirates (UAE) on June 23, and in Peru, and Morocco on Thursday.

CNBG will steadily pursue the international phase-3 clinical trials according to clinical research plans and continue to carry forward the cooperation with other countries and regions.

"We will ensure the availability and affordability of the vaccine and try to market it in China and aboard as soon as possible," CNBG said in the statement.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue